Stock Taper 
NSPR
$0.85
▼ DOWN 4.35% (-0.04)
KEY STATISTICS
Market Cap$39.81 M
52w High$2.57
52w Low$0.63
Dividend Yield—
Frequency—
P/E-1.33
Volume74.22K
Shares Out.46.84M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Marvin L. Slosman
COMPENSATION 2026
Salary$588,500
Stock Awards$1,541,231
Incentive Plan Pay$0
All Other Comp.$23,765
Total$3,095,187
ABOUT
SECTOR
Healthcare
WENT PUBLIC
April 12, 2011
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
127
PRICE TARGET
Target High$4.00
Target Low$3.00
Target Median$3.50
Target Consensus$3.50
UPCOMING EARNINGS
DateNov 10, 2026
DayTuesday
Rev. Est.$2.00M
NOV
10
TUE
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2021-04-27 | Reverse | 1:15 |
| 2019-04-01 | Reverse | 1:50 |
| 2018-02-08 | Reverse | 1:35 |
| 2016-10-10 | Reverse | 1:25 |
| 2015-10-13 | Reverse | 1:10 |
| 2015-10-01 | Reverse | 1:10 |
| 2012-12-21 | Reverse | 1:4 |
| 2011-04-11 | Forward | 3:1 |
PRICE
$0.85 ▼ DOWN 4.35% (−$0.04)About InspireMD, Inc.
https://www.inspiremd.com ↗InspireMD, Inc. develops and markets proprietary MicroNet stent technologies, including CGuard and MGuard systems, for vascular and coronary disease treatments across multiple regions, with ongoing development of peripheral vascular solutions.
INDUSTRY
Medical - Devices
A PRODUCT INSPIREMD, INC. IS KNOWN FOR
CGuard Prime Carotid Stent System
The CGuard Prime is an FDA-approved carotid stent with proprietary MicroNet mesh technology that traps plaque to prevent strokes, representing InspireMD's leading and latest product in stroke prevention.
Revenue by Products
| Icon | PRODUCT | Q3-2022 | Q1-2023 | Q2-2023 | Q3-2023 |
|---|---|---|---|---|---|
 | CGuard EPS | — | $1.24M | $1.65M ▲ | $1.56M ▼ |
 | CGuard | $1.43M | — | — | — |
Revenue by Geography
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
 | Other Countries | $1.14M | $1.27M ▲ | $1.31M ▲ | $1.11M ▼ |
 | ITALY | $293K | $353K ▲ | $354K ▲ | $304K ▼ |
 | GERMANY | $380K | $251K ▼ | $255K ▲ | $265K ▲ |
 | POLAND | $211K | $350K ▲ | $301K ▼ | $262K ▼ |
 | ARGENTINA | — | — | — | $180K |
 | UNITED STATES | $497K | $920K ▲ | $1.18M ▲ | -$351K ▼ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
50.23%
HOLDERS
57
TOP 12 OF 57 · RANKED BY POSITION SIZE
Rosalind Advisors, Inc.
Nantahala Capital Management, LLC
Abrdn Plc
Orbimed Advisors LLC
Parkman Healthcare Partners LLC
Velan Capital Investment Management LP
Marshall Wace, Llp
Soleus Capital Management, L.P.
Ghisallo Capital Management LLC
Pura Vida Investments, LLC
Ingalls & Snyder LLC
Huntleigh Advisors, Inc.
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2
INSIDER TRADES
★
DIRECTOR
Stuka Paul
Purchase · 20.0K shares
2026-05-27
★
OFFICER: CHIEF COMMERCIAL OFFICER
Gleason Shane Thomas
Sale · 1.6K shares
2025-05-27
★
OFFICER: CHIEF COMMERCIAL OFFICER
Gleason Shane Thomas
Sale · 2.9K shares
2026-02-02
★
OFFICER: CHIEF COMMERCIAL OFFICER
Gleason Shane Thomas
Sale · 2.5K shares
2025-01-30
MOST RECENT ANALYST GRADES
GRADE SUMMARY
OVERWEIGHT 1
1 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 RCEL | $10.35 | COMPARE |
 ORMP | $5.03 | COMPARE |
 VANI | $1.42 | COMPARE |
 HYPR | $0.83 | COMPARE |
 MBOT | $1.48 | COMPARE |
 IMA | $5.34 | COMPARE |
 CNTX | $0.38 | COMPARE |